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Multipotent stem/progenitor cells with similar developmental potentials have been independently identified from diverse human
tissue/organ cultures. The increasing recognition of the vascular/perivascular origin of mesenchymal precursors suggested blood
vessels being a systemic source of adult stem/progenitor cells. Our group and other laboratories recently isolated multiple
stem/progenitor cell subsets from blood vessels of adult human tissues. Each of the three structural layers of blood vessels: intima,
media, and adventitia has been found to include at least one precursor population, that is, myogenic endothelial cells (MECs),
pericytes, and adventitial cells (ACs), respectively. MECs and pericytes eﬃciently regenerate myofibers in injured and dystrophic
skeletal muscles as well as improve cardiac function after myocardial infarction. The applications of ACs in vascular remodeling and
angiogenesis/vasculogenesis have been examined. Our recent finding that MECs and pericytes can be purified from cryogenically
banked human primary muscle cell culture further indicates their potential applications in personalized regenerative medicine.
1. Introduction
Multipotent adult stem/progenitor cells have been identified
in nearly all human organs and extensively investigated to
date [1–6]. For example, the human bone marrow (BM)
functions as a diverse reservoir for several stem/progenitor
cell populations, including hematopoietic stem cells (HSCs),
multipotent mesenchymal stem/stromal cells (MSCs), and
endothelial progenitor cells (EPCs) [7, 8]. The human skele-
tal muscle contains committed myogenic precursors, skeletal
myoblasts, primitive myogenic stem cells, and satellite cells
[1]. On the other hand, the human fat harbors adipose
progenitor cells and adipose-derived stem cells (ADSCs)
which are functionally and phenotypically resembling the
BM-MSCs [9, 10].
However, many of these stem/progenitor cell popula-
tions have been identified retrospectively in ex vivo tissue
and organ cultures, such as multipotent adult progeni-
tor cells (MAPCs), mesoangioblasts, and MSCs [10–13].
This obscures the origin and the native identity of these
stem/progenitor cells in vivo. In order to fully utilize the
developmental potentials and therapeutic potencies of the
adult stem/progenitor cells, it is deemed important to
understand whether these diﬀerent populations of adult
stem/progenitor cells are developmentally and/or hierarchi-
cally connected. Due to the phenotypical and functional
similarities of several of these stem/progenitor cell popula-
tions, we hypothesized the existence of a common source
in the human body. In this paper, we will discuss this
newly emerged concept: blood-vessel-derived mesodermal
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stem/progenitor cells and their therapeutic applications in
the futuristic personalized regenerative medicine.
2. Stem/Progenitor Cell-Based Therapy
The use of stem/progenitor cells for cell-based therapy is
deemed promising owing to not only their high prolifera-
tive capacity and multilineage diﬀerentiation potential but
also their functionality in secretion of trophic molecules
and antienvironmental stress to promote cell survival.
Specifically, adult stem/progenitor cells from an abundant
autologous origin have the additional advantages over other
stem cell types: high availability, no immunogenicity, low
tumorigenicity, and with no associated ethical issues [14].
To eﬃciently repair/regenerate defective organs, the donor
stem/progenitor cells are expected to possess desirable thera-
peutic properties, for example, minimal side eﬀects, ability
to integrate into host tissue, diﬀerentiation into desired
cell lineages, paracrine eﬀect, immunomodulation, regula-
tion of tissue remodeling, and activation of endogenous
repair/regeneration mechanisms [15–18].
The therapeutic potentials of adult stem/progenitor
cells have been extensively investigated in the preclinical
and clinical studies. For instance, MSCs have been widely
explored in a number of phase I, II, and phase III clinical
trials for several indications such as cardiovascular dis-
ease, stroke, multiple sclerosis/amyotrophic lateral sclerosis,
Crohn’s disease, and osteogenesis imperfecta [19–21]. Many
other recent and ongoing human studies have chosen bone
marrow mononuclear cells (BM-MNCs), skeletal myoblasts,
EPCs, or ADSCs as their donor cell populations [16, 22–
24]. Unfortunately, in some cases, donor stem/progenitor
cells initially demonstrated encouraging outcome but later
on showed uneven success in clinical trials, especially in
the treatment of cardiovascular disease [16, 23]. Neverthe-
less, BM-MSCs, ADSCs, and other MSC-like mesodermal
stem/progenitor cells still hold great promise for tissue repair
and regeneration because of their multipotency, autologous
availability, immune tolerance and regulation and robust
paracrine secretion of trophic eﬀectors.
3. Blood Vessels as a Source of
Stem/Progenitor Cells
The evidence of the vascular wall as a source of stem/
progenitor cells has been demonstrated in the emerging
hematopoietic system in the early development of human
embryo and fetus [25]. The hematopoietic cells emerge in
close vicinity to vascular endothelial cells in both intra
and extraembryonic hematopoiesis. Specifically, a popula-
tion of angiohematopoietic stem cells expressing flk-1 and
angiotensin-converting enzyme (ACE) migrates from the
para-aortic splanchnopleura into the ventral part of the
aorta, where they give rise to hemogenic endothelial cells
and subsequently hematopoietic cells [25]. Furthermore,
hematopoietic cells also appear to develop from endothelium
in the embryonic liver and fetal bone marrow, albeit at a
much lower frequency.
The similarity between many human mesodermal stem/
progenitor cell populations that are retrospectively discov-
ered in tissue/organ cultures has made us hypothesize that
there exists a common, systemic source of stem/progenitor
cells in the adult human body [26]. Blood vessels, which
consist of three structural layers: tunica intima, tunicamedia,
and tunica adventitia distribute throughout nearly all human
organs where adult mesodermal stem/progenitor cells can
be identified [27]. Apart from tunica intima, in which
the subendothelial zone has been suggested as one of the
sources of endothelial progenitor cells (EPCs), the possibility
that other structural layers of the blood vessels harbor
stem/progenitor cells was recently demonstrated in tunicae
media and adventitia [26, 28, 29].
Perivascular cells, often known as vascular mural cells,
are the cells that surround tunica intima of the blood
vessels and constitute a major component of the vascular
wall [27, 30]. Microvascular pericytes, though similar but
distinct from vascular smooth muscle cells, closely encircle
endothelial cells in capillaries and microvessels (arterioles
and venules) in most human tissues [30–32]. Pericytes
are commonly regarded as a structural element of blood
vessels that regulate vascular contractility and support the
stability of blood vessels [33–35]. Intimate interactions
between pericytes and endothelial cells tightly relate to the
vascular growth, maturation, and remodeling [30, 34–36].
In addition, pericytes have been implicated in a number of
pathological conditions, making them the potential targets
for therapeutic interventions [36, 37].
Historically, the outmost layer of arteries and veins, the
tunica adventitia, has been considered as a mere structural
bystander constituted by collagen and fibroblasts. A number
of recent findings have led to the reevaluation of the active
role of tunica adventitia in cell traﬃcking, immune response
mediation, and vascular remodeling [38]. The importance
of the tunica adventitia in regenerative vascular medicine is
highlighted by the numerous reports describing the presence
of multipotent progenitors within the wall of arteries and
veins [29, 39–42]. In a vascular remodeling setting following
an injury, it has been shown that adventitial cells (ACs) start
a process of proliferation, migration, into the tunicae media
and intima, and diﬀerentiation into smooth muscle cells
[41, 43, 44].
We have previously investigated whether the blood ves-
sels contribute to stem/progenitor cell lineages other than
hematopoietic cells. Through immunohistochemistry and
flow cytometry analyses, we documented evidence showing
the existence of rare subsets of human blood vessel derived
stem cells (hBVSCs) in multiple human tissues, including
skeletal muscle, fat, and placenta.
4. The Three Musketeers: Myogenic Endothelial
Cells, Pericytes, and Adventitial Cells
We and other laboratories recently reported the existence
of three distinct subpopulations of mesodermal precursors
within the blood vessel walls through anatomic and molec-
ular identifications. At least one precursor subset, that is,
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Figure 1: Distinct morphology of the three purified subpopulations of human blood-vessel-derived stem cells (hBVSCs) in culture:
myogenic endothelial cell (MEC), pericyte, and adventitial cell (AC) (100x).
myogenic endothelial cells (MECs), pericytes, and adventitial
cells (ACs) (Figure 1), was contained in each of the three
tunicae of blood vessels: intima, media, and adventitia,
respectively [26, 40, 45–47].
Myogenic endothelial cells (MECs), which suggest a
developmental relationship between endothelial and myo-
genic cells, have been identified within the vasculatures of
human skeletal muscle at a very low frequency (<0.5%)
[45]. MECs uniquely coexpressed myogenic (CD56) and
endothelial cell markers (CD34 and CD144) and were iden-
tified by immunohistochemistry and flow cytometry. Using
fluorescent-activated cell sorting (FACS), we were able to
purify these cells to homogeny [45]. MECs (CD56+CD34+
CD144+CD45−) proliferate long term, retain a normal
karyotype, survive better under oxidative stress than CD56+
myogenic cells, and are not tumorigenic [45]. Cultured
MECs displayed mesenchymal developmental capacities,
including myogenesis, osteogenesis, chondrogenesis, and
adipogenesis, under appropriate inductive conditions in vitro
[45]. Their stem cell characteristics were further confirmed
by the expression of classic MSC markers and the mesoder-
mal diﬀerentiations in culture from clonally derived MECs
(Zheng et al., in revision). However, it is not clear yet whether
MECs give rise to authentic MSCs in culture. Based on the
phenotypic and functional similarities between MECs and
the previously reported murine-muscle-derived stem cells
(mMDSCs), we believe that MECs represent the human
counterpart of mMDSCs. In addition to MECs, which are
primarily located in the intimal compartment of the blood
vessels within human skeletal muscle, other distinct subsets
of multipotent stem/progenitor cells were recently found in
the perivascular compartment of the vasculature (tunicae
media and adventitia), not only within the skeletal muscle
but throughout the human body [26, 40, 46, 47].
Though microvascular pericytes have long been con-
sidered to possess mesenchymal plasticity, the lack of a
proper purification method undermined the character-
ization of this potential precursor population [48–50].
Recently, our group identified the native expression of
classic MSC markers by microvascular pericytes and further
discovered a collection of cell surface markers, that is,
CD146+CD34−CD45−CD56− that enabled us to prospec-
tively isolate homogenous pericyte populations by FACS
from multiple human organs [26]. Purified pericytes prolif-
erate long term and express CD146, NG2, PDGFR-β, alkaline
phosphatase (ALP), and α-smooth muscle actin (α-SMA),
with the absence of endothelial cell markers, including von
Willebrand factor (vWF), CD31, CD34, and CD144 [26, 46].
These cells can be eﬃciently expanded in vitro and demon-
strate robust mesodermal developmental potentials, at the
clonal level, by diﬀerentiating into osteogenic, chondrogenic,
adipogenic, and myogenic lineages under suitable inductive
conditions in vitro [26]. The MSC characteristics of these
CD146+CD34−CD45−CD56− pericytes can be maintained
for the long-term in culture. Their myogenic and osteogenic
capacities were further displayed by transplantation into
the muscle pocket of immunodeficient mice. To date, no
tumorigenicity of pericytes has been reported [26, 46]. We
hypothesized that these cells are one of the developmental
origins of MSCs [26].
In the past, fibroblasts that are capable of diﬀerentiating
into myofibroblasts/smooth muscle cells (SMCs) following
vascular injury have been regarded as the primary cellular
component of the tunica adventitia [38, 51]. Recent studies
have gradually uncovered the true identity of the cells
residing in this outmost layer of the blood vessels [42].
Cells located at the interface between the tunica adventitia
and media, the so-called “vasculogenic zone”, have been
identified as CD34+CD31− and described as progenitors
endowed with the ability to diﬀerentiate into endothelial
cells and participate in the blood vessel formation as well
as the pathogenesis of atherosclerosis [29, 41, 51]. The
concept that the tunica adventitia functions as a reservoir
for stem/progenitor cells is highlighted by a recent study in
which a population of CD34+CD31− progenitors residing
in human saphenous vein was described [40]. These cells
were localized in the tunica adventitia in situ and could
be isolated and expanded at the clonal level in vitro.
Our study also showed the stem cell characteristics of a
CD34+CD31−CD146− nonpericyte perivascular cell popu-
lation in the vasculature of human adipose and other tissues
[47]. The FACS-purified CD34+CD31−CD146− population
exhibited the phenotype and developmental potentials of
MSCs. Furthermore, immunohistochemistry revealed that
CD34+CD31−CD146− cells reside in tunica adventitia of
blood vessels in multiple human organs and similar to
pericytes, natively express classic MSC surface markers.
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5. Myogenic Endothelial Cells for Skeletal
Muscle Regeneration and Cardiac Repair
The therapeutic potential of MECs was first tested in
the severe combined immunodeficiency (SCID) mouse
model of cardiotoxin-injured skeletal muscle [45]. MECs
(CD56+CD34+CD144+CD45−) isolated from fresh human
muscle biopsies were shown to regenerate skeletal myofibers
more eﬀectively than skeletal myoblasts (SkMs, CD56+/
CD34−/CD144−/CD45−), endothelial cells (ECs, CD34+/
CD144+/CD56−/CD45−), and unpurified primary muscle
cells, with or without in vitro expansion. Injection of MECs
into skeletal muscle of mdx/SCID mice, a disease model of
Duchenne muscular dystrophy (DMD), also displayed an
eﬃcient regeneration of human skeletal myofibers, indicated
by positive staining of both dystrophin and human lamin
A/C [45]. Furthermore, after expansion in culture, clonal
MECs exhibited robust chondrogenesis and osteogenesis in
vivo after implantation into the hindlimb muscle pocket
of SCID mice (Zheng et al., in revision). These results
suggest the feasibility of utilizing MECs to treat various
musculoskeletal disorders.
The application of MECs in the cardiovascular disease
was examined in an immune-deficient mouse model of
acute myocardial infarction (AMI) [52]. Myocardial infarc-
tion was induced in SCID-nonobese diabetic (NOD/SCID)
mice by ligation of left anterior descending coronary
artery (LAD), and cells were immediately injected into the
ischemic myocardium. Cardiac function was assessed by
echocardiography. The results demonstrated a significant
improvement in cardiac contractility after intramyocardial
injection of MECs when compared with injections of SkMs
and ECs [52]. Transplanted MECs not only displayed robust
engraftment within the infarcted myocardium but also
stimulated angiogenesis, attenuated scar tissue formation,
and promoted proliferation and survival of endogenous
cardiomyocytes more eﬀectively than the other two cell
types [52]. This is presumably attributed to higher secretion
of vascular endothelial growth factor (VEGF), a potent
angiogenic factor, by MECs under hypoxia. Similar to
mMDSCs, MECs regenerated significantly more fast-skeletal
MHC-positive myofibers in the ischemic heart. A minor
fraction of engrafted MECs diﬀerentiated into and/or fused
with cardiomyocytes by expressing cardiomyocyte markers,
cardiac troponin-T, and -I [52]. These findings suggest that
MECs represent a promising stem cell subset within human
skeletal muscle, an accessible autologous tissue source, for
cardiac repair and regeneration.
6. Pericytes for Tissue Repair and Regeneration
The application of pericytes in regenerative medicine was
first examined in SCID mouse models of injured and
dystrophic skeletal muscle [26]. Microvascular pericytes
freshly sorted by FACS from human skeletal muscle were
injected into the hindlimb muscles of SCID-nonobese dia-
betic (NOD/SCID) mice that had been injured by intra-
muscular injection of cardiotoxin. The presence of regen-
erating human spectrin-positive myofibers was detected by
immunohistochemistry and confirmed by fluorescence in
situ hybridization of central human nuclei [26]. Quantifi-
cation showed that freshly sorted or long-term-cultured
pericytes produced more human myofibers than purified
SkMs and unpurified muscle cells, ruling out the possibility
that the myogenic potential observed in pericytes resulted
from a consequence of the contamination by myoblasts.
Most importantly, this myogenic potential can be general-
ized to pericytes residing in nonmuscle tissues. Placenta-,
white adipose tissue-, and pancreas-derived pericytes also
exhibited high myogenic potential in culture and in vivo,
yielding human dystrophin- or spectrin-positive myofibers
upon transplanted into mdx/SCID or cardiotoxin-treated
NOD/SCID mouse muscles [26]. Dellavalle et al. also
showed that pericytes sorted from healthy and dystrophic
human skeletal muscles by ALP expression regenerate human
myofibers in muscles of dystrophic immunodeficient mice
[46]. Very recently, the same group demonstrated that
pericytes residing in the postnatal skeletal muscle natively
participate in the skeletal myofiber development, and the
satellite cell compartment and further contribute to the
regeneration of injured/dystrophic skeletal muscle, using a
transgenic label of inducible Alkaline Phosphatase CreERT2
[53]. These results indicate that pericytes play a role in
muscle ontogeny and are endowed with robust myogenic
potential that can be applied to skeletal muscle repair and
regeneration.
With their inherent functions in the vascular physi-
ology, pericytes seem to match the criteria of the ideal
donor cell population for cardiovascular repair. Recently, we
investigated the hypothesis that transplantation of cultured
pericytes benefits the ischemic heart [54]. Briefly, long-term-
cultured human muscle pericytes were injected into acutely
infarcted hearts of NOD/SCID mice. Echocardiography
revealed a significant improvement of cardiac function in
pericyte-injected hearts. Pericytes exhibited cardioprotective
eﬀects such as promotion of angiogenesis, reduction of scar
formation, and inhibition of chronic inflammation (Chen
et al., submitted). Moreover, a human pericyte-based small-
diameter vascular graft has been successfully engineered with
high patency after long-term transplantation [55]. These
data suggest that pericytes serve as a promising donor cell
source for stem-cell-based cardiovascular therapy.
7. Adventitial Cells Exhibit
Multilineage Potential for Blood
Vessel and Tissue Regeneration
The potential application of ACs in the clinical settings
has thus far been focused on the cardiovascular repair
and regeneration. Campagnolo et al. recently demonstrated
that CD34+CD31− ACs interact with endothelial cells and
promote the formation and stabilization of the capillary-like
structures [40]. Most importantly, injection of adventitial in
a hindlimb ischemia mouse model cells showed a significant
proangiogenic eﬀect as demonstrated by a full blood flow
recovery as early as 7 days after-injection, indicating the
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therapeutic potential of ACs in angiogenesis/vasculogenesis
[40]. Very recently, Katare et al. further reported that
transplantation of ACs improves the repair of infarcted
hearts through angiogenesis involving microRNA-132 [56].
Together, these data indicate the therapeutic potential of
ACs in ischemic tissue repair. Interestingly, the use of ACs
derived from the umbilical artery, in conjunction with SMCs
of the same source, in tissue-engineered small-caliber vessel
constructs resulted in superior mechanical properties than
the same constructs using cells derived from the umbilical
vein, suggesting that ACs and SMCs originating from
diﬀerent sources may lead to distinct tissue characteristics in
regenerative medicine [57].
The application of ACs is not limited to postnatal angio-
genesis/vasculogenesis or cardiovascular repair. Though the
myogenic potential of ACs remains to be determined, we
and other authors have demonstrated that adventitial cells,
regardless of their tissue of origin, display features typical of
MSCs [40, 42, 47]. The ability of ACs to diﬀerentiate into
major mesodermal cell lineages, including osteogenesis and
chondrogenesis, suggests a likely contribution of these cells
to the formation/regeneration of surrounding mesenchymal
tissues after injury and further expands the potential clinical
applications of this unique hBVSC subset into the field
of musculoskeletal diseases [47]. Altogether, these reports
suggest that rather than a passive constituent of the vascular
wall, the adventitia is a dynamic reservoir of stem/progenitor
cells that participate in vascular remodeling and regeneration
of surrounding tissues.
8. Cryopreserved Human Skeletal Muscle
Culture as a Source of Myogenic hBVSCs
Despite the successful isolations of various lineages of
hBVSCs from fresh tissue biopsies, the prolonged procedure
of FACS purification and subsequent culture expansion com-
plicate the usage of these promising adult stem/progenitor
cell populations. Specifically, this represents a major hurdle
to the clinical translation of hBVSCs. We recently reported
that long-term cryopreserved human primary skeletal mus-
cle cell cultures (cryo-hPSMCs) include diverse cell popula-
tions; two subpopulations of hBVSCs, myogenic endothelial
cells (MECs) and pericytes/perivascular stem cells (PSCs),
can be purified from cryo-hPSMCs by FACS [58]. Due
to the frequent loss of CD34 and CD144 expression in
culture, another endothelial cell marker, UEA-1 receptor
(UEA-1R), was used for purification in this case. Cryo-
MECs express all three cell lineage markers (CD56+UEA-
1R+CD146+CD45−), and cryo-PSCs express only CD146
(CD146+CD56−UEA-1R−CD45−). The preservation of the
myogenic capacity of cryo-MECs and cryo-PSCs was demon-
strated by the regeneration of human spectrin-positive
myofibers after injections of newly sorted cells (with or with-
out culture expansion) into the cardiotoxin-injured skeletal
muscles of immunodeficient mice [58]. MECs showed the
highest regenerative capacity in the injured mouse muscles,
better than the unsorted muscle cells, CD56+ myoblasts, and
cryo-PSCs. Cryo-PSCs remained myogenically superior to
the unsorted cells and myoblasts. These findings suggest the
feasibility to further purify subpopulations of the hBVSCs
from banked human skeletal muscle cells, highlighting a new
approach to extract therapeutic stem/progenitor cells from
a cryogenically banked source for personalized regenerative
medicine.
9. Ontogeny and Heterogeneity, Innate
Factors Affecting the Therapeutic Potency of
Stem/Progenitor Cells?
MSCs represent a highly heterogeneous population of widely
studied but poorly defined multipotent stem/progenitor cells
[59]. Indeed, Guilak et al. have shown that only 52% of
the clones obtained from cultured ADSCs retain the ability
to diﬀerentiate into two or more mesodermal cell lineages
[60]. The presence of subsets of cells with limited or no
diﬀerentiation potential within the conventional stromal
cultures may therefore hamper the clinical eﬃcacy of these
promising stem/progenitor cells. This raised the possibility
that clinical trials based on the transplantations of the total
SVF or unfractionated MNCs often showed uneven success
because of the variable frequency of progenitors within the
total stroma [16, 23]. Additionally, mesenchymal progenitors
have mostly been selected by their plastic adherence and
expanded long-term in culture with reagents originated from
animals, which ultimately limits their clinical use due to FDA
regulations.
The identification of pericytes as, at least in part, the
ancestors of MSCs has represented a breakthrough in the
search for the true identity of MSCs [26]. Though this
has raised the possibility that most MSCs, if not all, are
derived from pericytes, other subsets of stem/progenitor cells
residing in the blood vessel walls may constitute part of
the MSC entity as described above [61]. The question of
whether all MSCs originate from microvascular pericytes
is partially answered by Tormin et al., who reported that,
in bone marrow, MSCs can be derived not only from
the subendothelial sinusoidal CD146+ cells, as previously
demonstrated by Sacchetti et al., but also from the bone-
lining CD146− cells [62, 63]. Furthermore, using the genetic
lineage tracing, Feng et al. recently reported MSCs from
both pericyte and nonpericyte origins diﬀerentiate into
odontoblasts and participate in tooth growth and repair in
mice, suggesting that the pericyte contribution to MSCs may
vary in diﬀerent tissues and possibly depend on the density
of the local vascularity [64].
Another good example that diﬀerent subsets of stem/
progenitor cells contributing to the MSC entity is from the
observation of the concurrent presence of two distinct sub-
populations of perivascular multipotent progenitor cells,
namely, CD34−CD31−CD146+microvascular pericytes and
CD34+CD31−CD146− adventitial cells, in the adipose
tissue [39, 47]. These two subpopulations of hBVSCs share
in situ and in vitro expression of typical MSC surface
markers, CD44, CD73, CD90, and CD105, but they are
phenotypically and anatomically distinct [39, 47]. Pericytes
are indeed defined as CD45−CD34−CD31−CD146+ cells
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Table 1: Comparison of hBVSC subpopulations and bone marrow MSCs.
MEC Pericyte AC BM-MSC
Native location Intima Media Adventitia Bone marrow
Cell surface marker profile for
cell sorting
CD34+
CD45−
CD56+
CD144+
CD34−
CD45−
CD56−
CD146+
CD31−
CD34+
CD45−
CD146−
N/A
Classic MSC marker expression
in culture
CD29+
CD44+
CD90+
CD105+
CD44+
CD73+
CD90+
CD105+
CD44+
CD73+
CD90+
CD105+
CD29+
CD44+
CD73+
CD90+
CD105+
Diﬀerentiation in vitro
Osteogenic (+)
Chondrogenic (+)
Adipogenic (ND)
Myogenic (+)
Osteogenic (+)
Chondrogenic (+)
Adipogenic (+)
Myogenic (+)
Osteogenic (+)
Chondrogenic (+)
Adipogenic (+)
Myogenic (ND)
Osteogenic (+)
Chondrogenic (+)
Adipogenic (+)
Myogenic (+)
Diﬀerentiation in vivo Myogenesis Myogenesis Osteogenesis Vasculogenesis
Osteogenesis
Chondrogenesis
Adipogenesis
Myogenesis
Cardiomyogenesis
Vasculogenesis
Potential clinical application
Skeletal musclere-
pair/regeneration;
Cardiac repair
Skeletal muscle
repair/regeneration;
Vascular
repair/regeneration
Vascular
repair/regeneration;
Cardiac repair
Bone repair;
Cartilage repair;
Tendon/ligament
repair; skeletal
muscle repair;
Vascular repair;
Cardiac repair;
Wound healing;
Immunoregulation
MEC: myogenic endothelial cell; AC: adventitial cell; BM-MSC: bone marrow mesenchymal stem/stromal cells; N/A: not available; ND: not determined.
Native tissue
MSC
Other
stromal
cells?
MEC
Pericyte
AC
MSC
DissociationA
MSC?D
CultureCCell sortingB
MEC-
derived 
Pericyte-
derived 
?
AC-
derived 
?
Figure 2: Schematic depiction of hBVSCs at the origin of mesenchymal stem/stromal cells (MSCs). (A) hBVSCs, including myogenic
endothelial cells (MECs, red), pericytes (green), and adventitial cells (AC, blue), are dissociated from fresh muscle biopsy and separated
from endothelial cells (yellow) and other cell types. (B) Dissociated cells are purified to homogeneity by fluorescence-activated cell sorting
(FACS) and newly sortedMECs, pericytes, and ACs already exhibit multilineage developmental potentials. (C) FACS-purified pericytes, ACs,
and possibly MECs give rise to authentic MSCs in long-term culture. (D) Nevertheless, whether native hBVSCs serve as a source of MSCs in
situ and participate in tissue repair and regeneration remains an open question.
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tightly surrounding microvessels, whereas CD45−CD34+
CD31−CD146− adventitial cells are located in the outmost
layer of larger blood vessels in the human adipose, a
literally unlimited tissue source. Both subpopulations of cells
are endowed with multilineage mesenchymal diﬀerentiation
capacity at the clonal level and represent ideal candidates
for the treatment of musculoskeletal and vascular diseases
[39, 40, 65]. Above all, both subpopulations are abundant
in lipoaspirate, and with the definitive phenotypes of each
hBVSC fraction, we can readily enrich both fractions by
cell sorting in order to improve their therapeutic eﬃciency
and safety [47]. Table 1 summarizes the basic characteristics
of hBVSC subpopulations and BM-MSCs as well as their
potential clinical applications.
Nevertheless, while all, or at least part of, the three
hBVSC subpopulations contributing to the MSC entity in
culture are gradually becoming an accepted notion; whether
the multilineage potentials are natively present within
hBVSC subsets and subsequently responsive to pathological
stimulations in vivo remains to be investigated (Figure 2).
Ultimately, the current therapeutic strategy based on the
transplantation of unfractionated stromal cells may in the
near future be replaced by the purification, combination, and
direct reinfusion of the distinct subsets of hBVSCs, devoid of
cells with none or a restricted regenerative potential.
10. Conclusion
In this paper, we discussed the newly emerged concept of
blood vessels as a systemic source of adult stem/progenitor
cells. Three subpopulations of hBVSCs, that is, MECs,
pericytes, and ACs have been respectively isolated from
diﬀerent layers of the blood vessels and examined in detail
for their developmental capacities and therapeutic potentials
in tissue repair and regeneration. Besides, the fresh tissue
biopsy, the cryogenically banked primary human skeletal
muscle culture was shown to be an alternative source of
myogenic subsets of hBVSCs, shedding new lights on the
future of the personalized regenerative medicine. Finally, the
identification of the precise phenotypes of distinct hBVSC
subpopulations represents not only an important milestone
for understanding the nature and origin of MSCs but also a
crucial step toward the improvement of stem/progenitor cell-
based therapies.
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